What is ENOV's health score?

Enovis CORP (ENOV) has a TradeApes health score of 48 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ENOV's estimated fair value?

Based on our 5-year discounted cash flow model, Enovis CORP's estimated fair value is $2.01 per share, representing a -91.6% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is ENOV undervalued or overvalued?

Our model currently rates ENOV as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ENOV... Refresh in a moment for the full analysis.

Enovis CORP (ENOV)

Healthcare Overvalued low mixed

$23.78

Updated: 2026-06-06

TradeApes Score

Financial Strength

30 Weak

Operating Trend

40 Weak

Relative Value

70 Healthy

Capital Allocation

55 Mixed

Risk

50 Mixed

Est. Fair Value $2.01

DCF Upside -91.6%

Sector Rank #3916 of 6846

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− High leverage — net debt/EBITDA between 3× and 5×

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.